Immunoscintigraphy
From Wikipedia, the free encyclopedia
Immunoscintigraphy is a nuclear medicine procedure used to find cancer cells in the body by injecting a radioactively labeled antibody, which binds predominantly to cancer cells and then scanning for concentrations of radioactive emissions.[1][2]
Clinical applications[edit]
Immunoscintigraphy is performed using a variety of radiopharmaceuticals, for a large range of purposes. Colorectal cancer is one of the most studied areas, with 111In or 99mTc labelled epitopes of the carcinoembryonic antigen.[3] The antibody capromab pendetide reacts with prostate membrane specific antigen (PMSA) and can be labelled with Indium-111.[4]
See also[edit]
References[edit]
- ^ "Imaging Techniques for the Diagnosis of Ovarian Cancers: Immunoscintigraphy". 21 December 2004.
- ^ "Immunoscintigraphy". NCI Dictionary of Cancer Terms. National Cancer Institute. Retrieved 1 June 2017.
- ^ Matzku, Siegfried; Stahel, Rolf A (1999). Antibodies in Diagnosis and Therapy. CRC Press. p. 143. ISBN 9789057023101.
- ^ Fass, Leonard (August 2008). "Imaging and cancer: A review". Molecular Oncology. 2 (2): 115–152. PMID 19383333. doi:10.1016/j.molonc.2008.04.001
.
 |
This immunology article is a stub. You can help Wikipedia by expanding it. |
